ABSTRACT
Background: The relationship of epidermal growth factor receptors (EGFR) pathway, such as PI3K, K-ras, and B-raf, with response to EGFR-targeted antibodies is less well studied. Aim: To assess sorafenib with cetuximab in treating metastatic colorectal cancer. Settings and Design: Thirty-five patients with metastatic colorectal cancer were randomized to receive cetuximab with or without oral sorafenib. Patients and Methods: Patients received cetuximab IV weekly for four weeks and oral sorafenib twice daily on days 1 - 28, with recycling every four weeks. The primary end point was the response rate (partial and complete), while the secondary end points were the adverse effects, time to progression and overall survival. Statistical Analysis was made using the Statistical Product and Service Solutions, using SPSS 10.0, with estimation of both time to progression and overall survival time by the Kaplan-Meier method and comparing the two groups with the use of a log-rank test. Results: Partial response was higher in cetuximab-sorafenib (EN), which constituted 33.3% compared to 17.6% in the cetuximab group (P = 0.44). Progression-free survival had a statistically higher significant difference in wild K-ras compared to mutant K-ras cases (P = .0001). Median overall survival was seven and five months in the (EN) and (E) groups respectively (P = 0.49). Conclusion: K-ras and B-raf was a predictor of response, so genotyping of tumors was needed for defining the patient population that was likely to benefit from the targeted therapy. A combination of therapy that simultaneously targets K-ras and B-raf could be a useful approach to increase the number of patients who may benefit from anti-EGFR therapy.
Subject(s)
Adult , Aged , Antibodies, Monoclonal/administration & dosage , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Benzenesulfonates/administration & dosage , Colorectal Neoplasms/drug therapy , Colorectal Neoplasms/pathology , Female , Follow-Up Studies , Humans , Liver Neoplasms/drug therapy , Liver Neoplasms/secondary , Male , Middle Aged , Neoplasm Recurrence, Local/drug therapy , Neoplasm Recurrence, Local/pathology , Pyridines/administration & dosage , Survival Rate , Treatment OutcomeABSTRACT
No abstract available.
Subject(s)
Adult , Aged , Humans , Middle Aged , Antineoplastic Agents/administration & dosage , Antineoplastic Combined Chemotherapy Protocols , Benzenesulfonates/administration & dosage , Carcinoma, Hepatocellular/mortality , Chemoembolization, Therapeutic , Cisplatin/administration & dosage , Fluorouracil/administration & dosage , Infusions, Intra-Arterial , Liver Neoplasms/mortality , Pyridines/administration & dosage , Survival RateABSTRACT
Verificou-se o efeito do tratamento superficial do modelo de cera com o alquil benzeno sulfonato de sódio a 11 por cento na adaptaçäo de 2 revestimentos, um à base de cristobalita e outro, de quartzo. O método utilizado foi o da mensuraçäo do ângulo de contacto formado entre a cera e os revestimentos, estando a superfície da cera antes da inclusäo, tratada com detergente e deixada molhada, e, tratada, porém seca. O ângulo formado foi avaliado através de um microscópio de mensuraçäo Carl Zeiss com dispositivo apropriado. Verificou-se que o alquil benzeno sulfonato de sódio a 11 por cento, melhora a adaptaçäo do revestimento à base de quartzo, porém näo interfere na do revestimento à base de cristobalita, e que näo há superioridade de um método de tratamento sobre o outro, isto é, estando a superfície da cera molhada ou seca